Pasar al contenido principal

Nanophotonic label-free biosensors for precision medicine

RYC2020-029015-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ INSTITUT CATALÀ DE NANOCIÈNCIA I NANOTECNOLOGIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy

  • Batool, Razia|||0000-0001-6864-5655
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Singh, Rukmani|||0000-0002-7562-7217
  • Lechuga, Laura M.|||0000-0001-5187-5358
Immune checkpoint inhibitors (ICIs) emerged as promising immunotherapies for cancer treatment, harnessing the patient's immune system to fight and eliminate tumor cells. However, despite their potential and proven efficacies, checkpoint inhibitors still face important challenges such as the tumor heterogeneity and resistance mechanisms, and the complex in vitro testing, which limits their widespread applicability and implementation to treat cancer. To address these challenges, we propose a novel analytical technique utilizing biomimetic label-free nanoplasmonic biosensors for rapid and reliable screening and evaluation of checkpoint inhibitors. We have designed and fabricated a low-density nanostructured plasmonic sensor based on gold nanodisks that enables the direct formation of a functional supported lipid bilayer, which acts as an artificial cell membrane for tumor ligand immobilization. With this biomimetic scaffold, our biosensing approach provides real-time, highly sensitive analysis of immune checkpoint pathways and direct assessment of the blocking effects of monoclonal antibodies in less than 20 min/test. We demonstrate the accuracy of our biomimetic sensor for the study of the programmed cell death protein 1 (PD1) checkpoint pathway, achieving a limit of detection of 6.7 ng/mL for direct PD1/PD-L1 interaction monitoring. Besides, we have performed dose-response inhibition curves for an anti-PD1 monoclonal antibody, obtaining a half maximal inhibitory concentration (IC) of 0.43 nM, within the same range than those obtained with conventional techniques. Our biomimetic sensor platform combines the potential of plasmonic technologies for rapid label-free analysis with the reliability of cell-based assay in terms of ligand mobility. The biosensor is integrated in a compact user-friendly device for the straightforward implementation in biomedical and pharmaceutical laboratories. Graphical Abstract: (Figure presented.)
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nanoporous Graphene Integrated onto Bimodal Waveguide Biosensors for Detection of C-Reactive Protein

  • Lisboa, Bárbara|||0000-0002-3231-7411
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Singh, Rukmani|||0000-0002-7562-7217
  • Castro-Esteban, Jesús|||0000-0003-0100-943X
  • Peña, Diego|||0000-0003-3814-589X
  • Mugarza, Aitor|||0000-0002-2698-885X
  • Lechuga, Laura M.|||0000-0001-5187-5358
  • Moreno, Cesar|||0000-0003-2682-211X
Despite the outstanding progress in photonic sensor devices, a major limitation for its application as label-free biosensors for biomedical analysis lies in the surface biofunctionalization step, that is, the reliable immobilization of the biorecognition element onto the sensor surface. Here, we report the integration of bottom-up synthesized nanoporous graphene onto bimodal waveguide interferometric biosensors as an atomically precise biofunctionalization scaffold. This combination leverages the high sensitivity of bimodal waveguide interferometers and the large functional surface area of nanoporous graphene to create highly sensitive, selective, and robust biosensors for the direct immunoassay detection of C-reactive protein (CRP), an inflammatory biomarker widely used in the clinical diagnosis of infections and sepsis. The limit of detection was determined at 3 ng/mL, which is well below the clinical cutoff levels required for the diagnostic detection of CRP in patient samples. This innovative approach holds promise for transforming diagnostics, environmental monitoring, and various fields requiring precise biomolecular detection.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy

  • Batool, Razia
  • Soler, María
  • Colavita, Francesca
  • Fabeni, Lavinia
  • Matusali, Giulia
  • Lechuga, Laura M.
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 102 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC50) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer., Financial support is acknowledged from the SensCELL project (Ref. No. PGC-2018-099870), funded by the Spanish Ministry of Science and Innovation (MCIN), the Spanish Research Agency (AEI), and the European Regional Development Fund (ERDF), and from the CONVAT project (Ref. 101003544), funded by the H2020 Research and Innovation Programme of the European Commission (H2020-SC1-PHE-Coronavirus-2020). RB acknowledges the economic support (Ref. PRE2019- 089357) from MCIN and AEI linked to the project SEV-2017-0706-19-4. MS acknowledges the economic support of the Ramon y Cajal Grant (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. INMI also acknowledges funding from the European Virus Archive – GLOBAL (Grant No. 871029). The ICN2 is supported by the CERCA programme (Generalitat de Catalunya) and the Severo Ochoa Centres of Excellence programme, funded by the AEI (Grant. No. SEV-2017-0706)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel biomimetic nanoplasmonic sensor for rapid and accurate evaluation of checkpoint inhibitor immunotherapy

  • Batool, Razia
  • Soler, María
  • Singh, Rukmani
  • Lechuga, Laura M.
Immune checkpoint inhibitors (ICIs) emerged as promising immunotherapies for cancer treatment, harnessing the patient's immune system to fight and eliminate tumor cells. However, despite their potential and proven efficacies, checkpoint inhibitors still face important challenges such as the tumor heterogeneity and resistance mechanisms, and the complex in vitro testing, which limits their widespread applicability and implementation to treat cancer. To address these challenges, we propose a novel analytical technique utilizing biomimetic label-free nanoplasmonic biosensors for rapid and reliable screening and evaluation of checkpoint inhibitors. We have designed and fabricated a low-density nanostructured plasmonic sensor based on gold nanodisks that enables the direct formation of a functional supported lipid bilayer, which acts as an artificial cell membrane for tumor ligand immobilization. With this biomimetic scaffold, our biosensing approach provides real-time, highly sensitive analysis of immune checkpoint pathways and direct assessment of the blocking effects of monoclonal antibodies in less than 20 min/test. We demonstrate the accuracy of our biomimetic sensor for the study of the programmed cell death protein 1 (PD1) checkpoint pathway, achieving a limit of detection of 6.7 ng/mL for direct PD1/PD-L1 interaction monitoring. Besides, we have performed dose-response inhibition curves for an anti-PD1 monoclonal antibody, obtaining a half maximal inhibitory concentration (IC50) of 0.43 nM, within the same range than those obtained with conventional techniques. Our biomimetic sensor platform combines the potential of plasmonic technologies for rapid label-free analysis with the reliability of cell-based assay in terms of ligand mobility. The biosensor is integrated in a compact user-friendly device for the straightforward implementation in biomedical and pharmaceutical laboratories., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The research work has been mainly funded by the DANCE project, part of the Severo Ochoa—Women Talent Program (SO-WTP) of the Catalan Institute of Nanoscience and Nanotechnology (ICN2). RB received economic support (Ref. PRE2019-089357) from MCIN and AEI linked to the project SEV-2019–0706-19–4. MS received economic support from the Ramon y Cajal Grant (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. The ICN2 is supported by the Severo Ochoa Centres of Excellence Programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. ICN2 is funded by the CERCA programme (Generalitat de Catalunya). The NanoB2A group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament de Recerca i Universitats de la Generalitat de Catalunya., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanoporous Graphene Integrated onto Bimodal Waveguide Biosensors for Detection of C-Reactive Protein

  • Lisboa, Bárbara D.
  • Soler, María
  • Singh, Rukmani
  • Castro-Esteban, Jesús
  • Peña, Diego
  • Mugarza, Aitor
  • Lechuga, Laura M.
  • Moreno, César
Despite the outstanding progress in photonic sensor devices, a major limitation for its application as label-free biosensors for biomedical analysis lies in the surface biofunctionalization step, that is, the reliable immobilization of the biorecognition element onto the sensor surface. Here, we report the integration of bottom-up synthesized nanoporous graphene onto bimodal waveguide interferometric biosensors as an atomically precise biofunctionalization scaffold. This combination leverages the high sensitivity of bimodal waveguide interferometers and the large functional surface area of nanoporous graphene to create highly sensitive, selective, and robust biosensors for the direct immunoassay detection of C-reactive protein (CRP), an inflammatory biomarker widely used in the clinical diagnosis of infections and sepsis. The limit of detection was determined at 3 ng/mL, which is well below the clinical cutoff levels required for the diagnostic detection of CRP in patient samples. This innovative approach holds promise for transforming diagnostics, environmental monitoring, and various fields requiring precise biomolecular detection., Main funding source of the work has been the LEGOCHIP project, a FLAG-ERA project funded by the Spanish Research Agency (AEI, ref PCI2019–111890–2). Financial support is also acknowledged from the AMBROSIA project (European Commission, HORIZON-CL4–2022-DIGITAL-EMERGING-01–03, 101093166)., M.S. acknowledges economic support of the Ramon y Cajal Fellowship (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. CM was supported by Grant RYC2019-028110-I funded by MICIN/AEI/10.13039/501100011033 and by “ESF Investing in your future”, SUBVTC-2022-0010, PID2022-140827OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by FEDER, UE and CNS2023-144257 funded by MICIU/AEI/10.13039/501100011033 and by NextGenerationEU/PRTR. The ICN2 is supported by the Severo Ochoa Centres of Excellence Programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. ICN2 is funded by the CERCA programme (Generalitat de Catalunya). The NanoB2A group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament de Recerca i Universitats de la Generalitat de Catalunya. D.P. and J.C.E. acknowledge financial support from Spanish MCIN/AEI/10.13039/501100011033 and the European Regional Development Fund (ERDF) through grant PID2022-140845OB-C62, and from Xunta de Galicia (Centro de Investigación do Sistema Universitario de Galicia, 2023-2027, ED431G 2023/03)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Label-Free Photonic Biosensors: Key Technologies for Precision Diagnostics

  • Soler, María
  • Lechuga, Laura M.
With the rise of multidrug-resistant pathogens, emerging zoonotic viruses, and the increasing prevalence of cancer, the modernization of clinical diagnostics has become a critical priority. Label-free optical biosensors, including those based on plasmonics and silicon photonic technologies, offer promising solutions for highly sensitive molecular analysis, rapid assay times, and decentralized operation. However, important challenges must be addressed for their successful clinical implementation, including the miniaturization and integration in compact, automated devices and the direct analysis of complex human specimens, like blood. In this context, an overview of recent advancements and future perspectives in photonic biosensors are provided for clinical diagnostics. The critical limitations of these technologies are examined, and specific research objectives that need to be met to fully leverage the potential of photonic biosensors and accelerate their adoption in the clinical practice are proposed. Finally, the most innovative biosensor designs and methodologies are highlighted, along with their prospects for contributing to precision diagnosis and personalized medicine., M.S. acknowledges the economic support of the Ramon y Cajal Grant (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. The ICN2 is supported by the Severo Ochoa Centres of Excellence Programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. ICN2 is funded by the CERCA programme (Generalitat de Catalunya). The NanoB2A group is a consolidated research group (Grup de Recerca) of the Generalitat de Catalunya and has support from the Departament de Recerca i Universitats de la Generalitat de Catalunya., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

All-dielectric photonic nanoresonators for visible-range biosensing with cell-mimetic functionalization

  • Batool, Razia
  • Singh, Rukmani
  • Sterman, Raquel G.
  • Lechuga, Laura M.
  • Soler, María
All-dielectric nanophotonic sensors are emerging as powerful platforms for high-resolution, label-free detection, exploiting sharp Mie-type resonances in low-loss materials. These sensors offer key advantages over metallic counterparts, including biocompatibility, highly hydrophilic surfaces and negligible heating that preserves delicate biochemical assemblies. While most reported all-dielectric sensors operate in the infrared, where resonances are stronger, translation into the visible spectrum is highly desirable for biological sensing, offering compatibility with standard optical components and enhanced sample interaction. In this work, we present a cost-effective nanofabrication strategy for high-performance silicon-based nanoresonators operating in the visible range and integrated into compact light prism-coupling devices. Using hole-mask colloidal lithography, we reproducibly fabricate short-range ordered silicon nanodisk array sensors with refractometric resonances around 720 nm and narrow bandwidths. We demonstrate a bulk refractometric sensitivity of 543 nm per refractive index unit (nm RIU<sup>−1</sup>) and a detection resolution as low as 10<sup>−6</sup> RIU, superior to analogous nanoplasmonic sensors. Integration of these nanosensors into a small-footprint optofluidic device allows for time-resolved analysis of biochemical interactions in a user-friendly, semi-automated format. Finally, as a proof of concept, we demonstrate their stable and efficient functionalization with supported lipid bilayers as cell membrane-mimicking interfaces for advanced on-chip studies of cell interactions or cell activity monitoring., The research work has been funded through the PRIME project (PID2023-151524OB-I00), funded by MICIU/AEI/ 10.13039/501100011033 and by ERDF/EU. MS acknowledges the economic support of the Ramon y Cajal Grant (RYC2020-029015-I) funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. The ICN2 is supported by the Severo Ochoa Centres of Excellence Programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. ICN2 is funded by the CERCA programme (Generalitat de Catalunya)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evanescent Wave-Based Photonic Biosensors for the Design and Evaluation of Advanced Cancer Immunotherapies

  • Huertas, César S.
  • Lechuga, Laura M.
  • Soler, María
Personalized immunotherapies hold great promise for correcting cellular dysfunction, inhibiting tumor growth, and even achieving durable cancer eradication. However, conventional analytical methods used to design and evaluate immunotherapies often fall short as they typically cannot monitor cell activity in real time, lack multiplexed capabilities for rapid screening, and require complex sample preparation. These limitations impede a full understanding of the dynamic immune responses that drive therapeutic outcomes. Label-free optical biosensors based on evanescent wave interactions provide a compelling alternative, enabling sensitive, noninvasive, and high-resolution analysis of cellular regulation, signaling, and therapy-induced molecular changes. In this perspective, we highlight recent advances in optical biosensor technologies for molecular and cell analysis and explore their potential to accelerate the development, optimization, and precision application of next-generation immunotherapies., Financial support is acknowledged from the PRIME project (PID2023-151524OB-I00), funded by the Spanish Ministry of Science and Innovation (MICIN) through the Spanish Research Agency (AEI), cofunded by the European Regional Development Fund (FEDER, European Union). M.S. acknowledges financial support from the Ramon y Cajal Fellowship (RYC2020-029015-I) funded by the AEI/MCIN, cofounded by the European Social Fund Plus (ESF+, European Union). The ICN2 is supported by the Severo Ochoa Centers of Excellence Program, Grant CEX2021-001214-S, funded by the MCIN/AEI/10.13039.501100011033. ICN2 is funded by the CERCA program (Generalitat de Catalunya)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Silicon Photonic Biosensors in Clinical Diagnostics: Emerging Opportunities and Challenges

  • Ramirez-Priego, Patricia
  • Alonso-Fernández, Andrés
  • Soler, María
  • Lechuga, Laura M.
As health care systems worldwide seek to decentralize diagnostics and expand precision medicine, silicon photonic biosensors have become a compelling solution. Their development over the past decade, especially in the last 5 years, marks a significant convergence of photonics, nanotechnology, and biomedical engineering that aims to reshape the diagnostic landscape. This review presents a comprehensive analysis of advances in silicon photonic biosensors, focusing on key configurations including microring resonators, photonic crystals, interferometers, and other emerging transduction mechanisms. We discuss the integration of advanced surface functionalization strategies for efficient and robust bioreceptor immobilization, which is critical for reliable biomedical applications. We emphasize the translation of these devices into clinical settings, primarily in infectious diseases and cancer diagnostics. Finally, we address current limitations, such as fabrication complexity, microfluidic integration, and data interpretation, and outline future directions to enhance scalability and clinical adoption in personalized medicine and decentralized health care., We acknowledge financial support received for the TYPLEX Project (grant PDC2023-145891-I00), funded by the Spanish for Ministry of Science, Innovation and Universities/Spanish State Research Agency (MCIU/AEI/10.13039/501100011033) and the European Union NextGenerationEU/Recovery, Transformation and Resilience Plan (PRTR). M.S. acknowledges economic support from the Ramón y Cajal Fellowship (RYC2020-029015-I), funded by the AEI/MCIN and the European Union NextGenerationEU/PRTR. The Catalan Institute of Nanoscience and Nanotechnology (ICN2) is funded by the CERCA program/Generalitat de Catalunya and is supported by the Severo Ochoa Centres of Excellence program (grant CEX2021‐001214-S), funded by MCIU/AEI/10.13039.501100011033., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021‐001214-S), Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biomimetic nanoplasmonic sensor for rapid evaluation of neutralizing SARS-CoV-2 monoclonal antibodies as antiviral therapy

  • Batool, Razia|||0000-0001-6864-5655
  • Soler Aznar, Maria|||0000-0001-7232-2277
  • Colavita, Francesca
  • Fabeni, Lavinia|||0000-0002-2975-8611
  • Matusali, Giulia
  • Lechuga, Laura M|||0000-0001-5187-5358
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown the potential to prevent or neutralize the effects of COVID-19 in patients at very early stages, with a few formulations recently approved by the European and American medicine agencies. However, a main bottleneck for their general implementation resides in the time-consuming, laborious, and highly-specialized techniques employed for the manufacturing and assessing of these therapies, excessively increasing their prices and delaying their administration to the patients. We propose a biomimetic nanoplasmonic biosensor as a novel analytical technique for the screening and evaluation of COVID-19 mAb therapies in a simpler, faster, and reliable manner. By creating an artificial cell membrane on the plasmonic sensor surface, our label-free sensing approach enables real-time monitoring of virus-cell interactions as well as direct analysis of antibody blocking effects in only 15 min assay time. We have achieved detection limits in the 10 TCID50/mL range for the study of SARS-CoV-2 viruses, which allows to perform neutralization assays by only employing a low-volume sample with common viral loads. We have demonstrated the accuracy of the biosensor for the evaluation of two different neutralizing antibodies targeting both Delta and Omicron variants of SARS-CoV-2, with half maximal inhibitory concentrations (IC) determined in the ng/mL range. Our user-friendly and reliable technology could be employed in biomedical and pharmaceutical laboratories to accelerate, cheapen, and simplify the development of effective immunotherapies for COVID-19 and other serious infectious diseases or cancer.